Ftse Mib
32.656,83
-2,84%
DAX
18.002,02
-1,43%
S&P 500
5.422,10
-0,21%
NASDAQ
17.618,54
-0,28%
Bitcoin
65.214,92
-2,32%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Royalty Pharma PLC (RPRX) Royalty Pharma PLC (RPRX) Notizie

RPRX

Royalty Pharma (RPRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RPRX
DataOraFonteTitoloSimboloCompagnia
10/06/202422:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RPRXRoyalty Pharma PLC
04/06/202423:12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:RPRXRoyalty Pharma PLC
04/06/202422:15GlobeNewswire Inc.Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/06/202423:15GlobeNewswire Inc.Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured NotesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202422:59Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:RPRXRoyalty Pharma PLC
03/06/202414:39Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RPRXRoyalty Pharma PLC
28/05/202413:10GlobeNewswire Inc.Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionNASDAQ:RPRXRoyalty Pharma PLC
22/05/202422:10GlobeNewswire Inc.Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
22/05/202422:00GlobeNewswire Inc.Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineNASDAQ:RPRXRoyalty Pharma PLC
16/05/202423:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RPRXRoyalty Pharma PLC
13/05/202414:15GlobeNewswire Inc.Royalty Pharma to Present at Upcoming Investor ConferencesNASDAQ:RPRXRoyalty Pharma PLC
09/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RPRXRoyalty Pharma PLC
09/05/202413:00GlobeNewswire Inc.Royalty Pharma Reports First Quarter 2024 ResultsNASDAQ:RPRXRoyalty Pharma PLC
09/05/202412:45GlobeNewswire Inc.Royalty Pharma to Acquire Royalty Interest in Sanofi’s FrexalimabNASDAQ:RPRXRoyalty Pharma PLC
19/04/202414:15GlobeNewswire Inc.Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024NASDAQ:RPRXRoyalty Pharma PLC
17/04/202414:15GlobeNewswire Inc.Royalty Pharma Declares Second Quarter 2024 DividendNASDAQ:RPRXRoyalty Pharma PLC
28/02/202422:15GlobeNewswire Inc.Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:RPRXRoyalty Pharma PLC
15/02/202415:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:RPRXRoyalty Pharma PLC
15/02/202413:30GlobeNewswire Inc.Royalty Pharma Reports Q4 and Full Year 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
30/01/202422:15GlobeNewswire Inc.Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024NASDAQ:RPRXRoyalty Pharma PLC
19/01/202414:15GlobeNewswire Inc.Royalty Pharma Announces Dividend IncreaseNASDAQ:RPRXRoyalty Pharma PLC
08/01/202413:00GlobeNewswire Inc.Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RPRXRoyalty Pharma PLC
03/01/202422:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RPRXRoyalty Pharma PLC
27/11/202322:15GlobeNewswire Inc.Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx ConferenceNASDAQ:RPRXRoyalty Pharma PLC
16/11/202323:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:RPRXRoyalty Pharma PLC
13/11/202314:10GlobeNewswire Inc.Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai ProgramNASDAQ:RPRXRoyalty Pharma PLC
13/11/202314:00Business WireTeva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI ProgramNASDAQ:RPRXRoyalty Pharma PLC
08/11/202313:00GlobeNewswire Inc.Royalty Pharma Reports Third Quarter 2023 ResultsNASDAQ:RPRXRoyalty Pharma PLC
19/10/202313:59GlobeNewswire Inc.Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on EvrysdiNASDAQ:RPRXRoyalty Pharma PLC
16/10/202322:15GlobeNewswire Inc.Royalty Pharma Declares Fourth Quarter 2023 DividendNASDAQ:RPRXRoyalty Pharma PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RPRX

La tua Cronologia

MRTX
CDASHBTC
CryptoDash Token
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network